title: ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
abstract: Single-nucleotide polymorphisms (SNPs) in the gene coding for the efflux-transport protein ABCB1 (P-glycoprotein) are commonly inherited as haplotypes. ABCB1 SNPs and haplotypes have been suggested to influence the pharmacokinetics and therapeutic outcome of the tyrosine kinase inhibitor (TKI) imatinib, used for treatment of chronic myeloid leukemia (CML). However, no consensus has yet been reached with respect to the significance of variant ABCB1 in CML treatment. Functional studies of variant ABCB1 transport of imatinib as well as other TKIs might aid the interpretation of results from in vivo association studies, but are currently lacking. The aim of this study was to investigate the consequences of ABCB1 variant haplotypes for transport and efficacy of TKIs (imatinib, its major metabolite N-desmethyl imatinib [CGP74588], dasatinib, nilotinib, and bosutinib) in CML cells. Variant haplotypes - including the 61A>G, 1199G>A, 1236C>T, 1795G>A, 2677G>T/A, and 3435T>C SNPs - were constructed in ABCB1 complementary DNA and transduced to K562 cells using retroviral gene transfer. The ability of variant cells to express ABCB1 protein and protect against TKI cytotoxicity was investigated. It was found that dasatinib and the imatinib metabolite CGP74588 are effectively transported by ABCB1, while imatinib, nilotinib, and bosutinib are comparatively weaker ABCB1 substrates. None of the investigated haplotypes altered the protective effect of ABCB1 expression against TKI cytotoxicity. These findings imply that the ABCB1 haplotypes investigated here are not likely to influence TKI pharmacokinetics or therapeutic efficacy in vivo.
authors.affiliation: Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Karin
authors.initials: K
authors.lastname: Skoglund
authors.forename: Samuel Boiso
authors.initials: SB
authors.lastname: Moreno
authors.forename: Maria
authors.initials: M
authors.lastname: Baytar
authors.forename: Jan-Ingvar
authors.initials: JI
authors.lastname: Jönsson
authors.forename: Henrik
authors.initials: H
authors.lastname: Gréen
keywords: CGP74588; N-desmethyl imatinib; chronic myeloid leukemia; imatinib; pharmacogenetics
references.citation: Leuk Lymphoma. 2011 Feb;52(2):331-4
references.pmid: 21133723
references.citation: Drug Metab Dispos. 2008 Jul;36(7):1357-64
references.pmid: 18420784
references.citation: J Hum Genet. 2010 Nov;55(11):731-7
references.pmid: 20720558
references.citation: Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8
references.pmid: 2444983
references.citation: Blood. 2006 Jul 15;108(2):697-704
references.pmid: 16597591
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: Haematologica. 2012 Jun;97(6):907-14
references.pmid: 22207690
references.citation: Eur J Clin Pharmacol. 2010 Apr;66(4):383-6
references.pmid: 20054526
references.citation: Mol Pharmacol. 2002 Jul;62(1):1-6
references.pmid: 12065748
references.citation: Blood. 2004 Dec 1;104(12):3739-45
references.pmid: 15315971
references.citation: Drug Metab Dispos. 2010 Aug;38(8):1371-80
references.pmid: 20423956
references.citation: Cancer Treat Rev. 2009 Dec;35(8):692-706
references.pmid: 19733976
references.citation: J Clin Oncol. 2010 May 10;28(14):2381-8
references.pmid: 20385986
references.citation: Med Oncol. 2011 Mar;28(1):265-9
references.pmid: 20204543
references.citation: Clin Cancer Res. 2002 May;8(5):935-42
references.pmid: 12006504
references.citation: Ann Oncol. 2013 Mar;24(3):756-60
references.pmid: 23117072
references.citation: Leukemia. 2007 May;21(5):926-35
references.pmid: 17330101
references.citation: J Pharm Sci. 2008 Jun;97(6):2045-8
references.pmid: 17828752
references.citation: Pharmacogenetics. 2003 Aug;13(8):481-94
references.pmid: 12893986
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
references.pmid: 10716719
references.citation: Clin Pharmacol Ther. 2007 Jul;82(1):33-40
references.pmid: 17495881
references.citation: Cancer Res. 2001 Apr 15;61(8):3458-64
references.pmid: 11309308
references.citation: Biochem Pharmacol. 2003 Jun 1;65(11):1843-52
references.pmid: 12781336
references.citation: J Clin Pharmacol. 2011 Dec;51(12):1721-7
references.pmid: 21148045
references.citation: Lancet Oncol. 2011 Sep;12(9):841-51
references.pmid: 21856226
references.citation: Clin Pharmacol Ther. 2004 Jan;75(1):13-33
references.pmid: 14749689
references.citation: Ann Hematol. 2011 Jul;90(7):837-42
references.pmid: 21225261
references.citation: Clin Pharmacol Ther. 2001 Mar;69(3):169-74
references.pmid: 11240981
references.citation: Talanta. 2011 Feb 15;83(5):1466-71
references.pmid: 21238737
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Blood. 2006 Aug 15;108(4):1370-3
references.pmid: 16627755
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4750-8
references.pmid: 19584153
references.citation: J Biol Chem. 2007 May 11;282(19):14194-204
references.pmid: 17392277
references.citation: Mol Carcinog. 1995 Jul;13(3):129-34
references.pmid: 7619215
references.citation: Blood. 2007 Apr 15;109(8):3496-9
references.pmid: 17192396
references.citation: Br J Pharmacol. 2009 Oct;158(4):1153-64
references.pmid: 19785662
references.citation: Pharmacogenomics J. 2012 Apr;12(2):111-8
references.pmid: 20938465
references.citation: Cancer Chemother Pharmacol. 2013 Jan;71(1):209-18
references.pmid: 23070145
references.citation: Handb Exp Pharmacol. 2011;(201):261-83
references.pmid: 21103972
references.citation: Blood. 2010 Dec 23;116(26):6144-5; author reply 6145-6
references.pmid: 21183698
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995
references.citation: Blood. 2008 Sep 1;112(5):2024-7
references.pmid: 18524988
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3881-8
references.pmid: 18559609